Involvement of the infralimbic cortex and CA1 hippocampal area in reconsolidation of a contextual fear memory through CB1 receptors: Effects of CP55,940  by Santana, Fabiana et al.
Neurobiology of Learning and Memory 127 (2016) 42–47Contents lists available at ScienceDirect
Neurobiology of Learning and Memory
journal homepage: www.elsevier .com/ locate /ynlmeRapid CommunicationInvolvement of the infralimbic cortex and CA1 hippocampal
area in reconsolidation of a contextual fear memory through
CB1 receptors: Effects of CP55,940http://dx.doi.org/10.1016/j.nlm.2015.11.016
1074-7427/ 2015 Elsevier Inc. All rights reserved.
⇑ Corresponding author at: Psychobiology and Neurocomputing Lab, Biophysics
Department, Biosciences Institute, Federal University of Rio Grande do Sul (UFRGS),
Av. Bento Gonçalves 9500, Prédio 43422, Sala 216, CEP 91.501-970, Porto Alegre,
Rio Grande do Sul, Brazil.
E-mail address: quillfe@ufrgs.br (J.A. Quillfeldt).Fabiana Santana a,c, Rodrigo O. Sierra a,c, Josué Haubrich a,c, Ana Paula Crestani a,c,
Johanna Marcela Duran a,c, Lindsey de Freitas Cassini a,c, Lucas de Oliveira Alvares b,c, Jorge A. Quillfeldt a,c,⇑
a Psychobiology and Neurocomputing Lab, Institute of Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
bNeurobiology of Memory Lab, Biophysics Department, Biosciences Institute, Institute of Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
cGraduate Program in Neuroscience, Institute of Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Brazila r t i c l e i n f o
Article history:
Received 16 July 2015
Revised 9 November 2015
Accepted 28 November 2015
Available online 10 December 2015
Keywords:
Infralimbic cortex
Hippocampus CA1 area
Memory reconsolidation
Contextual fear conditioning
CP55,940a b s t r a c t
The endocannabinoid system (ECS) has a pivotal role in different cognitive functions such as learning and
memory. Recent evidence confirm the involvement of the hippocampal CB1 receptors in the modulation
of both memory extinction and reconsolidation processes in different brain areas, but few studies focused
on the infralimbic cortex, another important cognitive area. Here, we infused the cannabinoid agonist
CP55,940 either into the infralimbic cortex (IL) or the CA1 area of the dorsal hippocampus (HPC) of adult
male Wistar rats immediately after a short (3 min) reactivation session, known to labilize a previously
consolidated memory trace in order to allow its reconsolidation with some modification. In both
structures, the treatment was able to disrupt reconsolidation in a relatively long lasting way, reducing
the freezing response. To our notice, this is the first demonstration of ECS involvement in reconsolidation
in the Infralimbic Cortex. Despite poorly discriminative between CB1 and CB2 receptors, CP55,940 is a
potent agent, and these results suggest that a similar CB1-dependent circuitry is at work both in HPC
and in the IL during memory reconsolidation.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Converging evidence from several studies does not cease to
provide consistent support to a pivotal role for the endocannabi-
noid system (ECS) in different cognitive processes, with emphasis
in learning and memory (e.g., Basavarajappa, Nagre, Xie, &
Subbanna, 2014; Quillfeldt & de Oliveira Alvares, 2015, chap. 3;
Ratano, Everitt, & Milton, 2014). CB1 receptors are widely
expressed throughout the brain, with significant levels expressed
in areas such as the dorsal hippocampus, the basolateral amygdala
and the prefrontal cortex, all involved in learning and memory pro-
cesses (Herkenham et al., 1990; Marsicano & Kuner, 2008).
Endogenous cannabinoids such as anandamide (AEA) or 2-AG,
synthesized on demand, act as retrograde modulators of GABA
and Glutamate transmission, inhibiting their release inhibitneurotransmitter release by a retrograde action (Katona &
Freund, 2012; Kortleven, Fasano, Thibault, Lacaille, & Trudeau,
2011; Szabó et al., 2014).
A considerable amount of evidence indicates that previously
consolidated memories can become labile/unstable after retrieval
under certain ‘‘boundary” conditions: a reactivation session con-
sisting of a short-lasting re-exposition to the training context, in
the absence of the unconditioned stimulus, allows for the memory
trace to become susceptible again to pharmacological and behav-
ioral disruption, undergoing a subsequent re-stabilization process
known as reconsolidation (Duvarci & Nader, 2004). However, when
this reactivation session is prolonged beyond a certain critical
period, a different process takes place, with the creation of a new
trace where the conditioned response has a decreased expression
– a process called extinction (Bouton, Westbrook, Corcoran, &
Maren, 2006; De Oliveira Alvares, Genro, Diehl, Molina, &
Quillfeldt, 2008; Myers & Davis, 2007; Pedreira & Maldonado,
2003).
Previous findings from our lab show that the administration of
the agonist/endogenous CB1 ligand AEA into the hippocampus
impaired memory reconsolidation, while the selective CB1
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Molina, et al., 2008). Both drugs were also effective upon extinction
– when infused after a longer, 25 min re-exposure session –
however, with remarkable ‘‘opposite” effects: AEA facilitated and
AM251 impaired extinction (De Oliveira Alvares, Genro, Diehl,
Molina, et al., 2008).
Effects are not usually that clear when the endogenous ligand
anandamide is the drug of choice, since it is difficult to estimate
endogenous levels and predict the consequences of the unavoid-
able fact that they will pool with the exogenously administered
quantity (De Oliveira Alvares, Genro, Diehl, & Quillfeldt, 2008).
Despite AM251 having a clearcut effect – amnestic upon memory
consolidation and facilitatory upon retrieval – AEA was facilitatory
upon consolidation and had no effect upon retrieval (De Oliveira
Alvares, Genro, Diehl, & Quillfeldt, 2008). This may be due, at least
in part, to the fact that anandamide also acts as a TRPV1 endoge-
nous ligand (Ross, 2003). Indeed, a detailed study from our lab
revealed some involvement of the endovanilloid system in mem-
ory modulation, but only when strong aversive stimulus (shock)
is present: TRPV1 antagonist capsazepine was able to impair mem-
ory consolidation, while the agonist capsaicin did not affect any of
two different aversive tasks (Genro, de Oliveira Alvares, &
Quillfeldt, 2012).
Recent reports have suggested that endocannabinoid CB1
receptors in the infralimbic cortex (IL), located in the ventromedial
region of the prefrontal cortex, may have an important role in the
extinction of fear memories: the infusion of the CB1 agonist
WIN55212-2 (Lin, Mao, Su, & Gean, 2009), or the CB1 antagonist
cannabidiol (Do Monte, Souza, Bitencourt, Kroon, & Takahashi,
2013) into the IL was shown to facilitate fear memory extinction
in rats: despite being a poorly selective indirect CB1 antagonist,
cannabidiol is know to potentiate the effects of agonists, and in this
work, its effect was blocked by rimonabant, suggesting a CB1-
mediated action.
From a therapeutic point of view, extinction has been employed
to supress maladaptive memories, but not without its limitations:
the progressive decay of emotional response obtained usually do
not last and fear response is (spontaneously) recovered over time
(Liu et al., 2014; Revillo, Paglini, & Arias, 2014; Schiller et al.,
2008). Since memory reconsolidation seems able to modify the
original memory trace and different reports suggest that pharma-
cological and behavioral inhibition of the reconsolidation process
prevent the re-expression of the previously consolidated emotional
memories, reconsolidation seems quite promising in clinical terms
(Schiller et al., 2010; Yang, Huang, & Hsu, 2011). The endocannabi-
noid system has also been proposed as a promising therapeutic tar-
get for drugs devised to decrease the impact of maladaptive
memories such as those verified in PTSD – post-traumatic stress
disorder (De Carvalho, Pamplona, Cruz, & Takahashi, 2014;
Ratano et al., 2014), despite – to this point – clinical trials having
been mostly inconclusive (Bucherelli, Baldi, Mariottini, Passani, &
Blandina, 2006; Gazarini, Stern, Piornedo, Takahashi, & Bertoglio,
2014; Lee & Flavell, 2014).
The aim of this study was to verify the effect of the cannabinoid
agonist CP55,940, when infused either into the IL cortex, or into the
CA1 area of the dorsal HPC after a reactivation session of a contex-
tual fear conditioning.2. Materials and methods
One hundred twenty-one Wistar rats (270–320 g) from our
breeding colony were used. Animals were housed in plastic cages,
four to five per cage, under a 12 h light/dark cycle and at a constant
temperature of 24 ± 1 C, with water and food ad libitum. All exper-
iments were conducted in accordance to our federal legislation(Law 11794/2008) and local guidelines for animal care, and the
project, approved by the University Ethics Committee (CEUA/
UFRGS Project # 17862).
Rats were deeply anesthetized by an i.p. injection of ketamine/
xylazine (75 and 10 mg/kg, respectively) and bilaterally implanted
with 27-gauge guide cannulae aimed 1 mm above the CA1 area of
the dorsal hippocampus (AP: 4.0 mm, LL: ±3.0 mm, DV: 1.6 mm)
or IL (AP: +3.2 mm, LL: ±0.6 mm, DV: 4.0 mm) from bregma
(Paxinos & Watson, 1998). After a 1 week recovery from surgery,
animals were submitted to the behavioral procedures. Following
the behavioral experiments, subjects were sacrificed and their
brains dissected and preserved in 10% formaldehyde to verify the
correct position of the cannula. Only the 106 animals with the
correct cannula placement (see Fig. 3) were considered in the
statistical analysis.
The potent, non-selective cannabinoid receptor agonist
CP55,940, was dissolved in phosphate buffered saline (PBS,
isotonic) with 8% dimethylsulfoxide to a final concentration of
5 lg/lL (a safe hydrophobic vehicle regularly used in our and other
labs – see, e.g., De Oliveira Alvares et al., 2005, 2006; De Oliveira
Alvares, Genro, Diehl, & Quillfeldt, 2008; De Oliveira Alvares,
Genro, Diehl, Molina, et al., 2008). At the time of infusion, a 30-
gauge infusion needle was fitted into the guide cannulae, with its
tip protruding 1.0 mm beyond the guide cannula end, and aimed
either to the pyramidal cell layer either of the infralimbic cortex,
or – form comparative reasons – the CA1 area of the dorsal hip-
pocampus. In all experiments, a 0.5 lL volume was bilaterally
infused in each structure at a slow rate (20 lL/h), and the needle
removed after waiting for an additional 30 s.
The conditioning chamber consisted of an (indirectly) illumi-
nated Plexiglas box (20  23  22 cm), with a metallic grid floor
of parallel 0.1-cm caliber stainless steel bars spaced 1.0 cm apart.
In the training session of the Contextual Fear Conditioning (CFC),
rats were left to habituate for 3 min to the conditioning chamber
before receiving two 2-s, 0.7-mA footshocks separated by a 30-s
interval (the US or unconditioned stimulus) and kept in the condi-
tioning environment for an additional minute before returning to
their homecages.
In experiment I subjects were intrahippocampally infused with
CP55,940 immediately after training, in three different concentra-
tions (1, 5 and 10 lg/lL) in order to verify the effective concentra-
tion able to disrupt memory Consolidation (Fig. 1A). In experiment
II we evaluated if the observed effect was mediated by CB1 recep-
tors verifying if CP55,940 effect could be reversed by a concomi-
tant, subthreshold concentration of the CB antagonist AM251
(Fig. 1B). Since the effective concentration for intrahippocampally
infused AM251 was found to be 5.5 ng/side or 20 lM, dissolved
in 0.5 lL volume of vehicle (De Oliveira Alvares, Genro, Diehl, &
Quillfeldt, 2008; De Oliveira Alvares et al., 2005, 2006), with
2 mM being proven ineffective: that is why we employ 0.2 lM of
AM251 to revert the CP55.940 effect, a concentration well bellow
the minimum effective value. In experiments III and IV subjects
were infused with the effective CP55,940 concentration right after
a 180 s context re-exposure (reactivation session) 48 h after train-
ing, in order to observe Reconsolidation effects in two successive
tests, one 48 h after reactivation, and the other, 7 days later: these
Reconsolidation effects were verified for two different brain struc-
tures, the CA1 area of the dorsal Hippocampus (Fig. 2A), or the
Infralimbic cortex (Fig. 2B). In all tests, animals have their freezing
behavior recorded for 4 min in the same conditioning context
without the US.
Since data from all experimental groups was proven to be both
homoscedastic and normally distributed (Kolmogorov–Smirnov
test with Lilliefors’ correction, P > 0.05), results were analyzed
either with One-way ANOVA followed by a Tukey HSD post hoc test
(if needed) – experiments I and II has four independent groups
A 
0
20
40
60
80
100
0
20
40
60
80
100
Veh CP1ug/uL CP5ug/uL CP10ug/uL
a,b
Vehicle 
CP55,940 
CP55,940+AM251 
HPC 
TR TT 
Day 1 Day 3 
B 
Vehicle CP 5ug/uL AM0.2uM CP 5 + AM 0.2
Fig. 1. Concentration–response curve and CB1-dependence of CP55,940 behavioral
effects when infused into the dorsal HPC after CFC training: disruption of Memory
Consolidation. Experimental design is shown in the top of each panel. Data
presented as Mean ± SEM of percent freezing time. (A) Animals infused with
CP55,940 immediately after CFC training with different concentrations: only the
5 lg/lL group exhibited a significantly lower freezing level in the test (48 h later)
compared to its control and the 10 lg/lL groups (N = 8, 8, 8 and 8), One-Way
ANOVA with Tukey HSD post hoc test, P < 0.05; (B) CP55,940 effect is reverted by
concomitant infusion of subthreshold concentration of AM251: the CP 5 lg/lL
group exhibited a significantly lower freezing level in the test (48 h later) compared
to its control and the CP5 + AM0.2 groups (N = 8, 8, 8 and 6), One-Way ANOVA with
Tukey HSD post hoc test, P < 0.05 (see text for more details).
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Fig. 2. Effect of CP55,940 infused into the dorsal Hippocampus (HPC) or the
Intralimbic Cortex (IL), right after FC context reactivation: disruption of Memory
Reconsolidation. Experimental design is shown in the top panel. Data presented as
Mean ± SEM of percent freezing time. Animals infused with 5 lg/lL of CP55,940
either into (A) the HPC (N = 6 and 8) or (B) the IL cortex (N = 8 and 8), immediately
after a 180 s re-exposition to the conditioning context (a reactivation/recon-
solidation session) express significantly lower freezing levels observable both in the
3rd (Test 1) and 8th days (Test 2) after reactivation. ANOVA for Repeated Measures
showed significant effect for Groups and Sessions and Groups ⁄ Sessions Interac-
tion, P < 0.05 (see text for more details).
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Measures – experiments III and IV show data for 3 sessions of 2 dif-
ferent groups (Fig. 2A and B). Significance level was set at P < 0.05.
3. Results
3.1. CP55,940 infused into the HPC disrupts memory consolidation
though a CB1 mediated mechanism
Tree different concentrations of CP55,940 or its vehicle (DMSO
8% in buffered saline) were infused into the CA1 area of the dorsal
hippocampus (HPC) immediately after the training session of a
Contextual Fear Conditioning. One-Way ANOVA revealed that only
the 5 lg/lL concentration has had a significative effect (F(3,28)
= 6.344, P = 0.002, Fig. 1A, N = 8, 8, 8 and 8, respectively); post hoc
analysis with Tukey’s HSD test has shown that this concentration
differs significantly both from the Vehicle (P = 0.001) and theCP10 lg/lL (P = 0.033, Tukey post hoc test) groups. In order to con-
firm that that the poorly selective CP55,940 was indeed acting
through CB1 receptors, we infused it concomitantly to a subthresh-
old (non-effective) concentration of AM251: One way ANOVA
revealed significant effect of the drug alone at the 5 lg/lL concen-
tration (F(3,26) = 7.094, P = 0.001), differing significantly from the
vehicle (P = 0.001), and the CP5 + AM0.2 (P = 0.033, Tukey post
hoc test) groups, all the other groups being equal (Fig. 1B, N = 8,
8, 8 and 6, respectively). The area targeted was the pyramidal layer
of CA1 region of the dorsal hippocampus, bilaterally infused with
drug or its vehicle (see Fig. 3A).
3.2. Memory reconsolidation is disrupted by CP55,940 infused into the
HPC after reactivation
CP55,940 or its vehicle (DMSO 8% in PBS) were infused into the
CA1 region of the dorsal hippocampus immediately after the 180 s
reactivation session: Two-Way ANOVA for Repeated Measures
A 
B 
Fig. 3. Cannula placements in (A) dorsal Hippocampus or (B) Intralimbic Cortex: Nissl
staining of a coronal section showing the cannula lesion: drawing shows the
targeted points inside these brain structures, since the inserted mizzy needle
protrudes 1 mm below the tip of the cannula (adapted from Paxinos & Watson,
1998). Only animals with the correct cannula placement were considered in the
statistical analysis.
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and – most important – of Session ⁄ Group Interactions, F(2,24)
= 6.736, P = 0.005, but not of Sessions (F(2,24) = 2.971, P = 0.070),
meaning that these groups do not behave the same way along
the successive sessions, with a long lasting amnestic effect of
CP55,940 observable both in the first and the second test sessions,
remaining persistent up to the 11th day after training (Fig. 2A,
N = 6 and 8). Targeted area was the same of the preliminary
experiments above (see Fig. 3A).
3.3. Reconsolidation is also disrupted by the post-reactivation infusion
of CP55,940 into the IL
CP55,940 or its vehicle were also ninfused into the piramidal
layer of the Infralimbic cortex immediately after the 180 s reactiva-
tion session: Two-Way ANOVA for Repeated Measures has shown a
significant effect of Groups, F(1,14) = 15.458, P = 0.002, and, also
very important, of Session ⁄ Group Interactions, F(2,28) = 5.691,
P = 0.008, however without Sessions effect, (F(2,28) = 2.843,
P = 0.075), meaning that the CP55,940-treated group displays a rel-
atively long lasting amnestic effect, observable from 1 to 8 days
after re-exposure/reactivation (Fig. 2B, N = 8 and 8). The area bilat-
erally infused was the pyramidal layer of the Infralimbic area of the
ventromedial prefrontal cortex (see Fig. 3B).
4. Discussion
Our results show a similar involvement, either of the infralimbic
cortex or the CA1 region of the dorsal hippocampus, in theprocessing of memory reconsolidation of an aversive task mediated
by CB1 receptors. The potent, yet poorly selective (between CB1
and CB2 receptors) cannabinoid agonist CP55,940 was locally
infused in each of these brain areas. The effective concentration
of 5 lg/lL, suggested by previous works (Auclair, Otani, Soubrie,
& Crepel, 2000, Bialuk, Dobosz, Potrzebowski, & Winnicka, 2014),
was carefully confirmed here, both for effectiveness (Fig. 1A) and
CB1-dependence (Fig. 1B).
The fact that our agonist CP55,940 did not cause the facilitatory
effect we have previously described for anandamide (De Oliveira
Alvares, Genro, Diehl, Molina, et al., 2008) came as a surprise.
Indeed, the post-reactivation infusion of CP55,940 was more rem-
iniscent of systemic than intracerebral infusion studies – tow dif-
ferent contexts usually characterized by exactly opposite effects
(Ameri, 1999; De Oliveira Alvares, Genro, Diehl, Quillfeldt, 2008;
Quillfeldt & de Oliveira Alvares, 2015; Wilson & Nicoll, 2002). Try-
ing to replicate the facilitation of consolidation observed with AEA,
we investigated a broader concentration–response curve than the
one displayed in Fig. 1A (data not shown), to no avail.
This inconsistency can be attributed to two aspects. First, the
behavioral tasks used were different: AEA was assayed in the
Step-Down Inhibitory Avoidance for consolidation, while
CP55,940 was studied in CFC. Second, and more important, the
pharmacological differences between both substances – anan-
damide and CP55,940 in terms of affinity, efficacy, potency and,
especially, selectivity. While anandamide is just a partial agonist
of CB1 and does not bind to CB2, the most prominent endocannabi-
noid 2-AG is a full agonist for both receptors (Di Marzo & De
Petrocellis, 2012; Sugiura et al., 1997). CP55,940, that is much
more potent than D9-THC (Rinaldi-Carmona et al., 1996), has a
pharmacological profile similar to 2-AG’s, with a Ki of 0.6–5.0
and 0.7–2.6 nM for CB1 and CB2, respectively (Thomas, Gilliam,
Burch, Roche, & Seltzman, 1998), and also act as a GPR55 antago-
nist (Kapur et al., 2009). Thus, both agonists, AEA and CP55,940
are poorly selective in different ways. The facilitatory effect we
have described of AEA (De Oliveira Alvares, Genro, Diehl, &
Quillfeldt, 2008) may be explained by the endovanilloid modula-
tion: we found that of TRPV1 antagonist capsazepine blocks con-
solidation, but agonist capsaicin was ineffective of two aversive
tasks (Genro et al., 2012), which is consistent with the idea of
AEA acting through TRPV1.
That was not the case here. Despite the effective reversion of
CP55,940 effect by concomitant, subthreshold AM251 supporting
a CB1 mediation (Fig. 1B), the possible involvement of CB2, or even
the less well-known GPR55 receptors, may still not be fully dis-
carded as putative explanations for the ‘‘opposite” effect verified.
For instance, there is some recent challenge to the classic notion
that central neurons do not express CB2 receptors (Brusco,
Tagliaferro, Saez, & Onaivi, 2008): this could open new, interesting
avenues of investigation.
Finally, the absence of effect of an agonist in the highest concen-
tration probed normally comes as pharmacological good news,
because it confers reliability to the experiment in terms of speci-
ficity: the higher the concentration, the more probable it is to bind
to other, non-specific targets, where the effect could go from oppo-
site to neutral/compensating. In the case of AEA, also ineffective at
the higher concentrations (De Oliveira Alvares, Genro, Diehl, &
Quillfeldt, 2008), there is the additional burden represented by
the fact that the exogenously infused substance ‘‘pools” with the
identical, endogenously released molecules, producing a virtually
unknown ‘‘final concentration” (Quillfeldt & de Oliveira Alvares,
2015). Being an artificial ligand, CP55,940 probably does not
behave the same way.
Despite the chosen concentration of 5 lg/lL being based on a
post-acquisition paradigm – concerning only consolidation – it
was also shown to be effective upon the reconsolidation phase,
46 F. Santana et al. / Neurobiology of Learning and Memory 127 (2016) 42–47both when infused into the HPC (Fig. 2A) or the IL cortex (Fig. 2B),
an effect that remained stable for at least 8 more days.
As mentioned above, post-reactivation treatments can affect
either extinction or its ‘‘counterpart”, reconsolidation, depending
on the re-exposure time without the US (Bustos, Maldonado, &
Molina, 2009): despite involving a disruptive effect analogous to
that resulting from a real extinction procedure, we know we are
here dealing with reconsolidation, not extinction because exposure
time was too short (180 s) and unable to produce a newmemory as
takes place in na extinction (Bouton, 2004).
Despite the effect upon consolidation (Fig. 1A and B) differ from
previous AEA findings (De Oliveira Alvares, Genro, Diehl, &
Quillfeldt, 2008), the reconsolidation disruption was exactly the
same effect observed for AEA in the same reconsolidation, in this
same behavioral task (De Oliveira Alvares, Genro, Diehl, Molina,
et al., 2008). Thus, at least for the updating of a previously acquired
trace, cannabinoid agonists seem to consistently converge to a dis-
ruptive action upon reconsolidation. Also, the fact that the very
same concentrations of CP55,940 has produced nearly identical
effects when infused into such different brain areas, the neocortical
IL and the archicortical HPC (compare Fig. 2A and B), suggests that
the local circuitry and/or mechanisms involved may be share some
similarities.
The infralimbic region of the prefrontal cortex (IL) has been
characterized as a complex relay station acting upon cognitive
behavior regulating memory acquisition (Fincham & Anderson,
2006; Gilmartin & Helmstetter, 2010), consolidation (Laurent &
Westbrook, 2009) and extinction (Izquierdo, Wellman, & Holmes,
2006; Milad & Quirk, 2002; Thompson et al., 2010), both through
neurotransmitter modulation (Mueller, Porter, & Quirk, 2008)
and ample connections with other relevant brain areas (Barker,
Taylor, & Chandler, 2014). Chang and Maren (2010), e.g., has shown
that focal lesions in the IL impaired the retention of extinction in
Sprague–Dawley rats. Similarly, there is ample evidence on the
involvement of IL in memory extinction from studies applying
electrical stimulation during the extinction of FC, usually reducing
fear expression and facilitating the consolidation of extinction
(Maroun, Kavushansky, Holmes, Wellman, & Motanis, 2012;
Milad, Vidal-Gonzalez, & Quirk, 2004; Vidal-Gonzalez, Vidal-
Gonzalez, Rauch, & Quirk, 2006).
It was recently shown that D9-THC alone or co-administered
with cannabidiol, was able to persistently disrupt the reconsolida-
tion of a contextual fear memory up to 22 days (Stern et al., 2015).
Similar results has been obtained with WIN55,212, another potent
agonist, infused into a different cortical area, the Insular Cortex,
during reconsolidation of conditioning taste aversion (Kobilo,
Hazvi, & Dudai, 2007), and into the amygdala, during reconsolida-
tion of fear-potentiated startle (Lin, Mao, & Gean, 2006). Here, we
presented the first demonstration of the involvement of the Infral-
imbic Cortex in memory reconsolidation through a CB1-mediated
mechanism.
Taken together, these findings converge consistently in that, in
all these mutually interconnected brain areas, the ECS operates
modulating negatively the cognitive process knwon as reconsolidation
(see Quillfeldt & de Oliveira Alvares, 2015), and even an artificial
agonist such as CP55,940 was able to disrupt the aversive memory
trace when infused during its labile phase.Funding and disclosure
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